Zegocractin is under clinical development by CalciMedica and currently in Phase II for Pancreatitis. According to GlobalData, Phase II drugs for Pancreatitis does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Zegocractin LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Zegocractin overview
Zegocractin (CM-4620) is under development for the treatment of acute pancreatitis, inflammatory bowel disease, severe COVID-19 pneumonia, allergic asthma, acute kidney injury (AKI) associated with acute hypoxemic respiratory failure (AHRF), acute respiratory distress syndrome, rheumatoid arthritis and asparaginase-induced pancreatic toxicity. The drug candidate is administered as an intravenous emulsion, inhalational and oral route. It acts by targeting calcium release-activated calcium channel protein 1 (Orai1).
CalciMedica overview
CalciMedica, formerly Graybug Vision Inc, is a clinical-stage pharmaceutical company that develops next-generation products for the treatment of chronic vision-threatening diseases of the retina and optic nerve. Its pipeline products include auxora provides acute pancreatitis, asparaginase-induced pancreatic, toxicity in pediatric patients and acute kidney injury. CalciMedica chronic disease (oral) offers cm6336, chronic pancreatitis and rheumatoid arthritis. The company operates through its research center located in Baltimore, Maryland, the US. CalciMedica is headquartered in La Jolla, California, the US.
For a complete picture of Zegocractin’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
